Lorne Zinman
A5046488842- Amyotrophic Lateral Sclerosis Research
- Neurogenetic and Muscular Disorders Research
- Parkinson's Disease Mechanisms and Treatments
- Alzheimer's disease research and treatments
- Dysphagia Assessment and Management
- Neurological diseases and metabolism
- Dementia and Cognitive Impairment Research
- Genetic Neurodegenerative Diseases
- Voice and Speech Disorders
- Prion Diseases and Protein Misfolding
- Cerebral Palsy and Movement Disorders
- RNA Research and Splicing
- Botulinum Toxin and Related Neurological Disorders
- Cholinesterase and Neurodegenerative Diseases
- Peripheral Neuropathies and Disorders
- Myasthenia Gravis and Thymoma
- Mitochondrial Function and Pathology
- biodegradable polymer synthesis and properties
- Neurological Disease Mechanisms and Treatments
- Epigenetics and DNA Methylation
- Genomics and Rare Diseases
- Advanced Neuroimaging Techniques and Applications
- Parkinson's Disease and Spinal Disorders
- Stroke Rehabilitation and Recovery
- Cerebrospinal fluid and hydrocephalus
University of Toronto
2016-2025
Sunnybrook Health Science Centre
2016-2025
Health Sciences Centre
2016-2025
Sunnybrook Research Institute
2016-2024
Newcastle University
2023
Sunnybrook Hospital
2019-2023
Google (United States)
2020-2023
University Health Network
2004-2023
Toronto Rehabilitation Institute
2023
Systems, Applications & Products in Data Processing (Canada)
2023
Tofersen is an antisense oligonucleotide that mediates the degradation of superoxide dismutase 1 (SOD1) messenger RNA to reduce SOD1 protein synthesis. Intrathecal administration tofersen being studied for treatment amyotrophic lateral sclerosis (ALS) due mutations.We conducted a phase 1-2 ascending-dose trial evaluating in adults with ALS mutations. In each dose cohort (20, 40, 60, or 100 mg), participants were randomly assigned 3:1 ratio receive five doses placebo, administered...
Abstract MR-guided focused ultrasound (MRgFUS) is an emerging technology that can accurately and transiently permeabilize the blood-brain barrier (BBB) for targeted drug delivery to central nervous system. We conducted a single-arm, first-in-human trial investigate safety feasibility of MRgFUS-induced BBB opening in eloquent primary motor cortex four volunteers with amyotrophic lateral sclerosis (ALS). Here, we show successful using MRgFUS as demonstrated by gadolinium leakage at target site...
<b>Objective: </b> We aimed to determine the effectiveness of IV immunoglobulin (IVIG) in treatment patients with myasthenia gravis (MG) and worsening weakness a randomized, placebo-controlled, masked study. <b>Methods: Fifty-one due MG were randomized infusion 2 g/kg IVIG or an equivalent volume dextrose 5% water. The Quantitative Myasthenia Gravis (QMG) Score for Disease Severity, validated clinical composite scale, was calculated by observer at baseline days 14 28. <b>Results: In...
Bulbar motor deterioration due to amyotrophic lateral sclerosis (ALS) leads the eventual impairment of speech and swallowing functions. Despite these devastating consequences, no standardized diagnostic procedure for assessing bulbar dysfunction in ALS exists adequate objective markers have not been identified. In this paper, we consider measures function, which show promise forming basis a comprehensive, quantitative assessment ALS. These are based on four subsystems: respiratory,...
Abstract Mutations in proteins like FUS which cause Amyotrophic Lateral Sclerosis (ALS) result the aberrant formation of stress granules while ALS-linked mutations other impede elimination granules. Repeat expansions C9ORF72, major ALS, reduce C9ORF72 levels but how this impacts is uncertain. Here, we demonstrate that associates with autophagy receptor p62 and controls by autophagy. This requires to associate via Tudor protein SMN proteins, including FUS, are symmetrically methylated on...
Objective A noncoding hexanucleotide repeat expansion in C9orf72 is the most common cause of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). It has been reported that causes a downregulation transcripts, suggesting haploinsufficiency may contribute to disease pathogenesis. Two protein isoforms are generated from three alternatively spliced transcripts ; long form (C9‐L) short (C9‐S), their function(s) largely unknown owing lack specific antibodies. Methods...
Purpose To determine the mechanisms of speech intelligibility impairment due to neurologic impairments, decline was modeled as a function co-occurring changes in articulatory, resonatory, phonatory, and respiratory subsystems. Method Sixty-six individuals diagnosed with amyotrophic lateral sclerosis (ALS) were studied longitudinally. The disease-related subsystems quantified using multiple instrumental measures, which subjected principal component analysis mixed effects models derive set...
Amyotrophic lateral sclerosis (ALS) is a rapidly progressing, fatal disorder with no effective treatment. We used simple genetic models of ALS to screen phenotypically for potential therapeutic compounds. screened libraries compounds in C. elegans, validated hits zebrafish, and tested the most potent molecule mice small clinical trial. identified class neuroleptics that restored motility elegans was pimozide, which blocked T-type Ca2+ channels these stabilized neuromuscular transmission...
Objective This study examines reading aloud in patients with amyotrophic lateral sclerosis (ALS) and those frontotemporal dementia (FTD) order to determine whether differences patterns of speaking pausing exist between primary motor vs. cognitive-linguistic deficits, contrast healthy controls. Design 136 participants were included the study: 33 controls, 85 ALS, 18 either behavioural variant FTD (FTD-BV) or progressive nonfluent aphasia (FTD-PNFA). Participants ALS further divided into 4...